265 related articles for article (PubMed ID: 24295850)
21. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
22. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
23. A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
Veldhuyzen van Zanten S; Chiba N; Barkun A; Fallone C; Farley A; Cockeram A; Dallaire C; Simms L; Nicholls B
Can J Gastroenterol; 2003 Sep; 17(9):533-8. PubMed ID: 14532926
[TBL] [Abstract][Full Text] [Related]
24. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
25. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
[TBL] [Abstract][Full Text] [Related]
26. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Gisbert JP; Gisbert JL; Marcos S; Grávalos RG; Carpio D; Pajares JM
Aliment Pharmacol Ther; 1999 Oct; 13(10):1311-6. PubMed ID: 10540045
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
28. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
29. Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Nie Y; Li Y; Wu H; Sha W; Du H; Dai S; Wang H; Li Q
Helicobacter; 1999 Jun; 4(2):128-34. PubMed ID: 10382127
[TBL] [Abstract][Full Text] [Related]
30. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Alhalabi M; Alassi MW; Alaa Eddin K; Cheha K
BMC Infect Dis; 2021 Jul; 21(1):642. PubMed ID: 34218802
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
33. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
34. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
Wu DC; Hsu PI; Chen A; Lai KH; Tsay FW; Wu CJ; Lo GH; Wu JY; Wu IC; Wang WM; Tseng HH
Eur J Clin Invest; 2006 Nov; 36(11):803-9. PubMed ID: 17032348
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a bismuth-based quadruple therapy regimen for
Alsohaibani F; Alquaiz M; Alkahtani K; Alashgar H; Peedikayil M; AlFadda A; Almadi M
Saudi J Gastroenterol; 2020; 26(2):84-88. PubMed ID: 32295933
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
37. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
[TBL] [Abstract][Full Text] [Related]
38. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
[TBL] [Abstract][Full Text] [Related]
40. Eradication Rate of
Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]